Related references
Note: Only part of the references are listed.Phage therapy: Current status and perspectives
Andrzej Gorski et al.
MEDICINAL RESEARCH REVIEWS (2020)
Engineering a CRISPR Interference System To Repress a Class 1 Integron in Escherichia coli
Qingyang Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
The Future of Phage: Ethical Challenges of Using Phage Therapy to Treat Bacterial Infections
Jonathan Anomaly
PUBLIC HEALTH ETHICS (2020)
Lipid oligonucleotides as a new strategy for tackling the antibiotic resistance
Tina Kauss et al.
SCIENTIFIC REPORTS (2020)
Monoclonal Antibodies as an Antibacterial Approach Against Bacterial Pathogens
Daniel V. Zurawski et al.
ANTIBIOTICS-BASEL (2020)
Monoclonal antibodies as anti-infective products: a promising future?
E. Pelfrene et al.
CLINICAL MICROBIOLOGY AND INFECTION (2019)
Antimicrobial effect of commercial phage preparation Stafal® on biofilm and planktonic forms of methicillin-resistant Staphylococcus aureus
Milada Dvorackova et al.
FOLIA MICROBIOLOGICA (2019)
Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults
S. O. Ali et al.
CLINICAL MICROBIOLOGY AND INFECTION (2019)
Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria
Kaitlyn E. Kortright et al.
CELL HOST & MICROBE (2019)
Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus
Rebekah M. Dedrick et al.
NATURE MEDICINE (2019)
Current State of Compassionate Phage Therapy
Shawna McCallin et al.
VIRUSES-BASEL (2019)
Antimicrobial Activity of Exebacase (Lysin CF-301) against the Most Common Causes of Infective Endocarditis
Aubrey Watson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Non-traditional Antibacterial Therapeutic Options and Challenges
Ursula Theuretzbacher et al.
CELL HOST & MICROBE (2019)
CRISPR-cas system: biological function in microbes and its use to treat antimicrobial resistant pathogens
Muhammad Abu Bakr Shabbir et al.
ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS (2019)
Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment
Keiko Yamakawa et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Resistance Evolution against Phage Combinations Depends on the Timing and Order of Exposure
Rosanna C. T. Wright et al.
MBIO (2019)
A New Antisense Phosphoryl Guanidine Oligo-2′-O-Methylribonucleotide Penetrates Into Intracellular Mycobacteria and Suppresses Target Gene Expression
Yulia Skvortsova et al.
FRONTIERS IN PHARMACOLOGY (2019)
Sustained activity of novel THIOMAB antibody-antibiotic conjugate against Staphylococcus aureus in a mouse model: Longitudinal pharmacodynamic assessment by bioluminescence imaging
Chenguang Zhou et al.
PLOS ONE (2019)
2839. Efficacy, Pharmacokinetics (PK), and Safety Profile of Suvratoxumab (MEDI4893), a Staphylococcus aureus Alpha Toxin (AT)-Neutralizing Human Monoclonal Antibody in Mechanically Ventilated Patients in Intensive Care Units; Results of the Phase 2 SAATELLITE Study Conducted by the Public-Private COMBACTE Consortium
Bruno Francois et al.
Open Forum Infectious Diseases (2019)
Phage Therapy in the Postantibiotic Era
Fernando L. Gordillo Altamirano et al.
CLINICAL MICROBIOLOGY REVIEWS (2019)
Rationally designing antisense therapy to keep up with evolving bacterial resistance
Seyfullah Kotil et al.
PLOS ONE (2019)
Using Omics Technologies and Systems Biology to Identify Epitope Targets for the Development of Monoclonal Antibodies Against Antibiotic-Resistant Bacteria
Antonio J. Martin-Galiano et al.
FRONTIERS IN IMMUNOLOGY (2019)
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Xiulong Shen et al.
NUCLEIC ACIDS RESEARCH (2018)
Cationic amphiphilic bolaamphiphile-based delivery of antisense oligonucleotides provides a potentially microbiome sparing treatment for C. difficile
Arun K. Sharma et al.
JOURNAL OF ANTIBIOTICS (2018)
Advances in the delivery of antisense oligonucleotides for combating bacterial infectious diseases'
Xiao-Yan Xue et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2018)
A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia
Avanish K. Varshney et al.
PLOS ONE (2018)
Monoclonal antibody targeting the ß-barrel assembly machine of Escherichia coli is bactericidal
Kelly M. Storek et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Resistance Development to Bacteriophages Occurring during Bacteriophage Therapy
Frank Oechslin
VIRUSES-BASEL (2018)
CRISPR-Cas antimicrobials: Challenges and future prospects
Elizabeth Pursey et al.
PLOS PATHOGENS (2018)
Adapted Bacteriophages for Treating Urinary Tract Infections
Aleksandre Ujmajuridze et al.
FRONTIERS IN MICROBIOLOGY (2018)
Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections
Shun Xin Wang-Lin et al.
ANTIBODIES (2018)
Phage therapy: progress in pharmacokinetics
Muhammad Imran Qadir et al.
BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2018)
Safety and Tolerability of 514G3, a True Human Anti-Protein A Monoclonal Antibody for the Treatment of S. aureus Bacteremia
Toan Huynh et al.
Open Forum Infectious Diseases (2017)
FDA-Approved Oligonucleotide Therapies in 2017
Cy A. Stein et al.
MOLECULAR THERAPY (2017)
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
M. H. Wilcox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Endotoxin neutralization by an O-antigen specific monoclonal antibody: A potential novel therapeutic approach against Klebsiella pneumoniae ST258
Valeria Szijarto et al.
VIRULENCE (2017)
Editorial: Phage Therapy: Past, Presentand Future
Stephen T. Abedon et al.
FRONTIERS IN MICROBIOLOGY (2017)
The state-of-play and future of antibody therapeutics
Zehra Elgundi et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Multiple Modes of Action of a Monoclonal Antibody against MultidrugResistant Escherichia coli Sequence Type 131-H30
Luis M. Guachalla et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Obiltoxaximab: Adding to the Treatment Arsenal for Bacillus anthracis Infection
Audrey W. Hou et al.
ANNALS OF PHARMACOTHERAPY (2017)
Pharmacokinetics of Monoclonal Antibodies
Josiah T. Ryman et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Challenges and Opportunities of Nontraditional Approaches to Treating Bacterial Infections
Brian N. Tse et al.
CLINICAL INFECTIOUS DISEASES (2017)
Using CRISPR-Cas systems as antimicrobials
David Bikard et al.
CURRENT OPINION IN MICROBIOLOGY (2017)
Safety of antisense oligonucleotide and siRNA-based therapeutics
Xuan Chi et al.
DRUG DISCOVERY TODAY (2017)
Chemical Strategies To Target Bacterial Virulence
Megan Garland et al.
CHEMICAL REVIEWS (2017)
An overview on safety of monoclonal antibodies
Andrea Matucci et al.
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Antisense antimicrobial therapeutics
Erin K. Sully et al.
CURRENT OPINION IN MICROBIOLOGY (2016)
Host-directed therapies for infectious diseases: current status, recent progress, and future prospects
Alimuddin Zumla et al.
LANCET INFECTIOUS DISEASES (2016)
Biofilm control with natural and genetically-modified phages
Amir Mohaghegh Motlagh et al.
WORLD JOURNAL OF MICROBIOLOGY & BIOTECHNOLOGY (2016)
Safety and efficacy of phage therapy via the intravenous route
Peter Speck et al.
FEMS MICROBIOLOGY LETTERS (2016)
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Richard S. Geary et al.
ADVANCED DRUG DELIVERY REVIEWS (2015)
Novel Phage Lysin Capable of Killing the Multidrug-Resistant Gram-Negative Bacterium Acinetobacter baumannii in a Mouse Bacteremia Model
Rolf Lood et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Antisense Growth Inhibition of Methicillin-Resistant Staphylococcus aureus by Locked Nucleic Acid Conjugated with Cell-Penetrating Peptide as a Novel FtsZ Inhibitor
Jingru Meng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Antisense Oligonucleotide Therapies: The Promise and the Challenges from a Toxicologic Pathologist's Perspective
Kendall S. Frazier
TOXICOLOGIC PATHOLOGY (2015)
Construction of a chimeric lysin Ply187N-V12C with extended lytic activity against staphylococci and streptococci
Qiuhua Dong et al.
MICROBIAL BIOTECHNOLOGY (2015)
Safety and Pharmacokinetic Profiles of Phosphorodiamidate Morpholino Oligomers with Activity against Ebola Virus and Marburg Virus: Results of Two Single-Ascending-Dose Studies
Alison E. Heald et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
siRNA-mediated gene silencing of MexB from the MexA-MexB-OprM efflux pump in Pseudomonas aeruginosa
Feng-Yun Gong et al.
BMB REPORTS (2014)
Effectiveness of bacteriophages in the sputum of cystic fibrosis patients
E. Saussereau et al.
CLINICAL MICROBIOLOGY AND INFECTION (2014)
Mechanisms of Neutralization of a Human Anti-α-toxin Antibody
Vaheh Oganesyan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases
Robert J. Citorik et al.
NATURE BIOTECHNOLOGY (2014)
Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials
David Bikard et al.
NATURE BIOTECHNOLOGY (2014)
A multifunctional bispecific antibody protects against Pseudomonas aeruginosa
Antonio DiGiandomenico et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Anti-infective monoclonals step in where antimicrobials fail
Jeffrey L. Fox
NATURE BIOTECHNOLOGY (2013)
The Future of Antibiotics and Resistance
Brad Spellberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Treatment of HCV Infection by Targeting MicroRNA
Harry L. A. Janssen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays
Josee Golay et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2012)
2012 and beyond: potential for the start of a second pre-antibiotic era?
Peter C. Appelbaum
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Silencing disease genes in the laboratory and the clinic
Jonathan K. Watts et al.
JOURNAL OF PATHOLOGY (2012)
Synthetic RNA silencing in bacteria - antimicrobial discovery and resistance breaking
Liam Good et al.
FRONTIERS IN MICROBIOLOGY (2011)
The safety and side effects of monoclonal antibodies
Trevor T. Hansel et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Antibodies for the treatment of bacterial infections: current experience and future prospects
Christopher Bebbington et al.
CURRENT OPINION IN BIOTECHNOLOGY (2008)
Effects of short interfering RNA against methicillin-resistant Staphylococcus aureus coagulase in vitro and in vivo
K Yanagihara et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Efficiency of antisense oligonucleotide drug discovery
CF Bennett
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2002)
Monoclonal antibody to tumor necrosis factor-α reduces hypergastrinemia in Helicobacter pylori infection
ILP Beales
AMERICAN JOURNAL OF MEDICINE (2001)
Share Paper
